Rapid Assay Brain Natriuretic Peptide and Troponin I in Patients Hospitalized With Decompensated Heart Failure (from the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness Trial)††Conflict of interest: Dr. Christenson is a consultant and serves on a speakers bureau for Biosite, Inc. (<$20,000/year).

American Journal of Cardiology

Volumn 100, Issue 9, 2007, Pages 1427-1433

  Shah, Monica R ^a   Hasselblad, Vic ^b   Tasissa, Gudaye ^b   Christenson, Robert H ^c   Binanay, Cynthia ^b   O'Connor, Christopher M ^b   Ohman, E Magnus ^b   Stevenson, Lynne W ^d   Califf, Robert M ^b  

^a WASHINGTON HOSPITAL CENTER   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; TROPONIN I;

ADULT; AGED; ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORRELATION COEFFICIENT; FEMALE; HEART FAILURE; HEART RIGHT ATRIUM PRESSURE; HEMODYNAMICS; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; LUNG CAPILLARY; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROTEIN DETERMINATION; PULMONARY ARTERY CATHETER;

EID: 35348867531     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2007.06.035     Document Type: Article

References (8)

1. ESCAPE Investigators and ESCAPE Study Coordinators. Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial. JAMA 294 (2005) 1625-1633
2. Bettencourt P., Azevedo A., Pimenta J., Frioes F., Ferreira S., and Ferreira A. N-terminal pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation 110 (2004) 2168-2174
3. Hartmann F., Packer M., Coats A.J., Fowler M.B., Krum H., Mohacsi P., Rouleau J.L., Tendera M., Castaigne A., Anker S.D., et al. Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial. Circulation 110 (2004) 1780-1786
4. Anand I.S., Fisher L.D., Chiang Y.T., Latini R., Masson S., Maggioni A.P., Glazer R.D., Tognoni G., Chon J.N., and Val-HeFT Investigators. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trail (Val-HeFT). Circulation 107 (2003) 1278-1283
5. Logeart D., Thabut G., Jourdain P., Chavelas C., Beyne P., Beauvais F., Bouvier E., and Solal A.C. Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. J Am Coll Cardiol 43 (2004) 635-641
6. Missov M., Calzolari C., and Pau B. Circulating cardiac troponin I in severe congestive heart failure. Circulation 96 (1997) 2953-2958
7. Horwich T.B., Patel J., MacLellan W.R., and Fonarow G.C. Cardiac troponin I is associated with impaired hemodyanmics, progressive left ventricular dysfunction, and increased mortality rates in advanced heart failure. Circulation 108 (2003) 833-838
8. Gheorghiade M., Gattis Stough W., Adams Jr. K.F., Jaffe A.S., Hasselblad V., and O'Connor C.M. The Pilot Randomized Study of Nesiritide Versus Dobutamine in Heart Failure (PRESERVD-HF). Am J Cardiol 96 suppl (2005) 18G-25G